GlaxoSmithKline PLC (GSK)

GSK (NYSE:Drugs) EQUITY
$42.84
neg -0.06
-0.14%
Today's Range: 0.00 - 0.00 | GSK Avg Daily Volume: 2,790,100
Last Update: 09/30/16 - 7:09 AM EDT
Volume: 0
YTD Performance: 6.32%
Open: $0.00
Previous Close: $42.90
52 Week Range: $37.82 - $45.58
Oustanding Shares: 2,436,200,000
Market Cap: 106,388,854,000
6-Month Chart
TheStreet Ratings Grade for GSK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 3 2 1
Moderate Buy 0 0 0 0
Hold 3 3 3 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.86 2.00 2.20 2.60
Latest Dividend: 0.49
Latest Dividend Yield: 5.00%
Dividend Ex-Date: 08/10/16
Price Earnings Ratio: 25.10
Price Earnings Comparisons:
GSK Sector Avg. S&P 500
25.10 179.60 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.04% 14.22% -15.02%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.00 -0.20 -0.06
Net Income 181.50 0.60 0.17
EPS 189.50 0.70 0.20
Earnings for GSK:
EBITDA 5.79B
Revenue 35.44B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.77 $0.65 $2.57 $2.69
Number of Analysts 1 1 5 5
High Estimate $0.77 $0.65 $2.65 $2.84
Low Estimate $0.77 $0.65 $2.44 $2.53
Prior Year $0.71 $0.55 $2.26 $2.57
Growth Rate (Year over Year) 8.45% 18.18% 13.81% 4.51%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Which stocks will be most favored by the corporate-bond purchases?
This market is like a leaky helium balloon; watch out for sudden downdrafts.
The drug maker continued to rally Monday.
GlaxoSmithKline and Google's parent Alphabet announced their joint plan to pioneer a new form of electronic medical treatment.
The U.K. isn't going anywhere Brexit vote notwithstanding, and here's a way to get on the most business-friendly state across the pond.
If you think the best thing to do post-Brexit is buy more, here are 4 to consider.
GSK has been largely stuck between $44 on the upside and $37 on the downside for the past 12 months.
The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.

Columnist Conversations

The integrity of the channel parameters on the General Electric GE chart could be a tell as to the short-to-in...
In mid August we added some Dec QCOM calls on a rollup, we take these off now. SOLD QCOM DEC 62.5 CALL AT 6...
Seeing a similar early start to trading as of yesterday.  Open pretty flat follow by reversal, especially...
Not pretty, but former net/net (and current double-net) up 15% yesterday on 2 1/2 times normal average volume ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.